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ABSTRACT
Uterine sarcomas are an uncommon and heterogeneous group of tumors that 
account for 3-7% of the malignant neoplasms of the uterus and approximately 
1% of all malignant tumors of the female genital system. The main clinical 
manifestations are abnormal uterine bleeding in pre- or postmenopausal 
women. Pelvic pain, abdominal distension, urinary urgency, and profuse and 
fetid leukorrhea are other frequent complaints. The authors present a case of a 
48-year-old patient that was in amenorrhea for 2 years, who sought treatment 
for vaginal bleeding. On physical examination, the abdomen was distended, 
painful in the hypogastrium and upon examination of the external genitalia, it 
was observed the exteriorization of an amorphous “mass”. The patient was 
submitted to uterine curettage. The results of the histological examination 
revealed leiomyosarcoma. Staging workup showed an enlarged uterus 
with endometrial lesion, and non-calcified pulmonary nodules. The patient 
underwent a pan-hysterectomy and chemotherapy, and is under oncologic 
treatment. The authors call attention for the unusual form of presentation of 
this entity.
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CASE REPORT
A 48-year-old, married, Caucasian female 
patient sought the emergency room complaining of 
vaginal bleeding and vaginal expulsion of a fetid and 
amorphous material. She referred a recent diagnosis 
of fibroids. Her past obstetric history included Gravidity 
4, Parity 4. Her last menstrual period was 2 years ago.
On physical examination the patient was 
in good general condition, pale, hydrated, blood 
pressure = 140/90 mmHg, weight = 70 kg, height = 150 
cm (BMI = 31). The abdomen was distended and painful 
in hypogastrium with an increased uterine volume 
reaching the umbilical scar. Upon examination of the 
external genitalia, it was observed the exteriorization 
of an amorphous “mass,” foul-smelling, and pinkish 
gray, measuring approximately 30 cm by the vagina 
(Figure 1).
On speculum examination, the cervix was 
not able to be identified due to the large amount 
of expulsed material in the vagina. The bimanual 
examination was not performed due to technical 
obstacles. Laboratory tests are shown in Table 1.
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Because of extensive bleeding during the 
curettage, 600 mL of packed red blood cells were 
transfused. Ceftriaxone and metronidazole were 
prescribed.
Histological examination revealed spindle-
shaped cells neoplasm with moderate to severe cellular 
atypia, moderate cellularity, more than 10 mitoses 
per 10 high power fields, with extensive necrosis 
(Figures 3 and 4). The immunohistochemical panel 
(Table 2) associated with histological criteria favored 
the diagnosis of uterine leiomyosarcoma.
The patient presented an uneventful outcome, 
was discharged after 3 days of hospitalization and 
referred to an oncologic center.
The transabdominal pelvic ultrasonography 
showed an enlarged uterus (residual uterine 
volume = 705 cm3, reference value (RV)* = 75.8 cm3) 
and heterogeneous myometrium with scattered multiple 
nodules. A submucosal fibroid in continuity with the 
cervix was expulsed into the vagina. No free liquid 
was observed into the recto-uterine pouch.
Under general anesthesia, the patient was 
submitted to curettage of the uterine cavity. The 
expulsed tumor plus the tissue removed by the 
procedure resulted in the 2000 grams of fetid bloody 
tissue, mixed with a purulent secretion (Figure 2).
* Mauad Filho F, Beduschi AF, Alberge R, et al. Avaliação  ultra-sonográfica 
das variações do volume uterino. Rev Bras Ginecol Obstet [online]. 
2001;23:175-9.
Figure 1 – Vaginal expulsion of a voluminous, amorphous and pinky mass. 
Table 1 – Initial laboratory workup
RV RV
Hemoglobin 10 12.3-15.3 g/dL INR 1.13 1.0
Hematocrit 31.4 36.0-45.0% Urea 19 5-25 mg/dL
Leucocytes 9280 4.4-11.3 × 103/mm3 Creatinine 0.5 0.4-1.3 mg/dL
Bands 5 1-5% Potassium 5.0 3.5-5.0 mEq/L
Segmented 54 45-70% Sodium 141 136-146 mEq/L
Eosinophils 0 1-4% ALT 10 9-36 U/L
Basophils 0 0-2.5% AST 14 10-31 U/L
Lymphocytes 35 18-40% Total bilirubin 0.24 0.3-1.2 mg/dL
Monocytes 6 2-9% Cai+ 1.11 1.11-1.4 mmol/L
Platelets 627.103 150-400 ×103/mm3
ALT = alanine aminotransferase; AST = aspartate aminotransferase; Cai+ = ionized calcium; INR= international normalized ratio; RV = reference value.
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Aiming the control of pain and bleeding, pan- 
hysterectomy was carried out and chemotherapy with 
100 mg/m2 docetaxel and 900 mg/m2 gemcitabine every 
3 weeks was started. Size reduction of the pulmonary 
nodules was observed after 4 cycles of chemotherapy. 
The surgical specimen revealed a uterus weighing 
875 g and measuring 13.0 × 7.5 × 6.0 cm. A bosselated 
smooth nodule was identified in the lower portion 
After 2 months, vaginal bleeding recurred, 
requiring hospitalization and packed red blood cells 
transfusion. The tumor staging workup showed the 
enlarged uterus with an infiltrative endometrial lesion, 
and non-calcified pulmonary nodules in the left upper 
lobe. Secondary involvement was highly suspected 
in the right lower lobe (Figures 5 and 6).
Figure 2 – Multiple irregular winy tissue fragments removed from the uterine cavity by curettage.
Figure 3 – Photomicrography of the expulsed tumoral mass. A - Overview of the leiomyosarcoma, showing 
pleomorphic hypercellular tissue with areas of necrosis (arrow), hemorrhage, (HE 100X); B - Numerous 
atypical mitosis (arrow), with over 15 mitoses/10 high power field (HE 400X); C - Intense nuclear pleomorphism 
(arrow) (HE 400X); D - Area of necrosis and bacterial proliferation, with colonies of bacteria (arrow).
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The immunohistochemical panel results are shown 
in Table 3, and were compatible with the diagnosis 
of uterine leiomyosarcoma.
The patient is currently under treatment in 
the sixth cycle of chemotherapy, without respiratory 
symptoms, and presented no further episodes of 
bleeding
DISCUSSION
The uterine sarcomas are an uncommon and 
heterogeneous group of tumors of mesodermal origin, 
accounting for 3–7% of malignant tumors of the uterus 
and approximately 1% of all malignant tumors of the 
of the uterus. Histologically, this mass proved to 
be a high-grade sarcoma with 14 cm in its longest 
axis, restricted to the uterus. The mitotic index was 
greater than 20 mitoses, necrosis was present, but 
angiolymphatic invasion was not detected. The 
ovaries and fallopian tubes were free of neoplasia. 
Figure 4 – Photomicrography of the expulsed tumoral mass – immunohistochemistry. A - Positive reaction 
for smooth muscle actin (HE 400X); B - Positive reaction for desmin (HE 400X).
Table 2 – Immunohistochemical panel 
Antibody Result Antibody Result
S100 Negative CD34 Negative
CD10 Positive* CD117 Inconclusive
Desmin Positive Ki67 Positive 50%
SMA Positive AE1/AE3 Negative
SMA= smooth muscle actin; * = Positive in rare cells.
Figure 5 – Abdominal end pelvic computed tomography. A - Coronal reformation showing increased uterine 
volume with tumoral invasion of the lateral wall of the uterus; B - Axial plane, showing in detail the tumoral 
infiltration of the uterine wall.
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mullerian tumor, was formerly classified among 
malignant mesenchymal tumors of the uterine body, 
with an incidence of approximately 40%.15 This 
neoplasia is rare, highly aggressive, and currently 
considered a metaplastic carcinoma and not another 
sarcoma.16 In the latest edition (2009) of the ‘TNM 
Classification of Malignant Tumours’17, the same 
classification of uterine carcinoma was applied for 
Carcinosarcoma of the uterus. Based on molecular, 
epidemiological, genetic and histopathological data, 
most authors support the monoclonal hypothesis of 
the origin of this tumor, which states that primary 
malignant epithelial cells are presumably subjected 
to mesenchymal metaplasia.18,19
Thus, leiomyosarcoma is the most common 
uterine sarcoma, which, in turn, is an aggressive tumor 
associated with a high risk of recurrence and death.9
Histologically, smooth-muscle tumors that 
show minimal or no atypia and are without coagulative 
necrosis, are classed as leiomyomas, regardless of 
mitotic count, whereas tumors showing moderate to 
severe atypia and coagulative necrosis are classed 
as leiomyosarcomas.20 Many characteristics are 
taken into account for malignancy diagnosis in 
leiomyosarcomas, including mitotic index, nuclear 
atypia, coagulative necrosis, cellularity, degree of 
differentiation and cellular pleomorphism, vascular 
invasion, and invasion of the surrounding myometrium. 
Among these histological characteristics, the mitotic 
index greater than 10 mitoses per 10 high-power 
fields, the degree of cytologic atypia, and the presence 
or absence of coagulative necrosis, are the most 
important predictors of the tumoral behavior.20,21 In a 
study comprising 28 cases of leiomyosarcomas, Jones 
and Norris (1995),22 showed that a tumor size greater 
than 3.0 cm, and patient age greater than 50 years 
are also factors associated with a worse prognosis.
female genital tract. Compared to endometrial tumors 
of epithelial origin, uterine sarcomas present more 
aggressive behavior and have a poor prognosis. In 
the U.S., the incidence of uterine sarcoma varies 
from 0.36 to 1.7/100,000 women/year.1-4 The uterine 
sarcomas predominantly affect women from 40 to 
60 years old, predominately in those of African 
descent.4 The average age at diagnosis is 55 years 
for leiomyosarcomas and 10 years later for the stromal 
sarcoma and endometrial carcinosarcoma.5
Similar to the uterus carcinomas, obesity, age 
(after menopause), and nulliparity are recognized as 
risk factors for uterine sarcomas,6 as well as previous 
pelvic irradiation,7 the use of tamoxifen,8 and genetic 
syndromes such as leiomyomatosis and hereditary 
renal carcinom.9-11
The histology of the main types of uterine 
sarcomas includes leiomyosarcoma (40%), endometrial 
stromal sarcoma (10-15%), and undifferentiated 
sarcoma (6%). Other histologic types include 
adenosarcoma (5.5-9%) and other rare uterine 
sarcomas, which are also classified as pure 
heterologous sarcomas (e.g. rhabdomyosarcoma, 
alveolar soft part sarcoma, angiosarcoma, liposarcoma, 
chondrosarcoma, and osteosarcoma).1,12-14 The 
carcinosarcoma, also known as malignant mixed 
Table 3 – Immunohistochemical panel of the 
surgical specimen
Antibody Result Antibody Result
SMA Positive Caldesmon Focally Positive 
CD10 Positive AE1/AE3 Negative
Desmin Negative Pancytokeratin Negative
SMA = smooth muscle actin.
Figure 6 – A and B - Axial thoracic computed tomography. Lung window, showing scattered nodules 
throughout the lung parenchyma, compatible with metastases.
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Leiomyosarcoma develops from smooth muscle 
and only 30% of cases are submucosal in origin, 
which may explain the unusual presentation of this 
case report.26 Sarcoma expulsion is most often seen 
in cases of adenosarcoma, a rare cancer of polypoid 
pattern originated from the endometrium. This sarcoma 
may be expulsed through the cervical orifice when 
the tumor size assumes large proportions.27
Diagnosis can be made by biopsy or 
endometrial curettage or, with some frequency, by 
histopathology fragment of polypoid mass expulsed 
by the cervix as seen in this case report. However, in 
retrospective series, the sensitivity of this diagnostic 
approach was about 60%. Therefore, the diagnosis 
is usually confirmed after hysterectomy.28
The low incidence, clinical diversity behavior, 
and histology of uterine sarcomas contribute to the 
lack of consensus on their treatment, which can vary 
according to the type of sarcoma, its stage, and the 
patient’s age.13 Local recurrence, and hematogenic 
spread to the lungs are common, as was observed in 
this case. The treatment of choice for gynecological 
sarcomas is a total hysterectomy accompanied by 
oophorectomy, lymphadenectomy, and cytological 
evaluation of peritoneal fluid. However, in the case 
of young patients, this approach is still under debate.
Giuntoli et al.10, in reviewing 208 patients with 
the diagnosis of uterine leiomyosarcoma, observed 
that the degree of tumor differentiation and advanced 
stage of disease were the main prognostic factors 
that could affect the patient’s survival rate. Moreover, 
they observed a significant reduction in the rate of 
recurrence with the use of adjuvant radiotherapy, 
without affecting overall survival. Regarding the 
preservation of the ovaries, there was no difference 
in survival or recurrence rates. Finally, there was no 
difference in the rate of survival among patients who 
underwent lymphadenectomy. Adjuvant chemotherapy 
with docetaxel and gemcitabine for four cycles is an 
option for treatment of tumors that invade the body 
and cervix of the uterus.29
The treatment for metastatic disease is based 
on chemotherapy. A Phase II study of 29 patients with 
leiomyosarcoma showed a 10% complete response 
rate and a 43% partial response rate when treated 
with a combination of gemcitabine and docetaxel. 
The overall survival time was 17.9 months.30
In the case of localized leiomyosarcoma, 
hysterectomy is the treatment of choice. In these cases, 
Regarding the differential diagnosis between 
uterine sarcomas, the immunohistochemical study is 
of paramount importance. Among tumor markers that 
can be used in the panel, some are more specific for 
the diagnosis of leiomyosarcoma, such as smooth-
muscle actin, desmin, histone deacetylase 8 (HDCA8), 
h-caldesmon, and oxytocin receptor (oxytocin 
receptor).1,14,23-24 In the case reported here, beyond 
the morphological characteristics, presence of necrosis 
and high mitotic index, both immunohistochemical 
studies were compatible with the diagnosis of uterine 
leiomyosarcoma. While, in the specimen obtained by 
curettage, the positivity for SMA and Desmin support 
this diagnosis, in the specimen of the excised uterus 
the positivity for SMA and Caldesmon confirm the same 
diagnosis. The discrepancy between the results for 
Desmin may be explained by difference in material 
representation, it does not alter the final diagnosis.
The leiomyosarcoma commonly presents as 
a rapidly growing uterine mass. Abnormal uterine 
bleeding in pre- or postmenopausal women, in the form 
of menorrhagia, is the most common initial symptom. 
Pelvic pain, abdominal distension, urinary urgency 
and profuse and fetid leukorrhea are other common 
complaints.25 On physical examination, 70-80% of 
patients present increased uterine volume, which 
is often difficult to differentiate from a myomatous 
uterus. Clinical suspicion of uterine sarcoma should 
be suspected in the case of rapid growth of uterine 
volume.
The case reported here called attention to 
the unusual manifestation of leiomyosarcoma in a 
patient that was in amenorrhea for 2 years without 
a previous history of irregular bleeding. Despite the 
prior diagnosis of fibroids, amenorrhea associated with 
the vaginal expulsion of an amorphous bloody tissue 
raised the initial diagnosis of abortion in progress. 
This diagnosis was ruled out with a negative result of 
β-HCG (human chorionic gonadotropin beta) and the 
ultrasound image of expulsed submucosal “fibroid.” 
Thus, the first hypothesis in this case was vaginal 
fibroid expulsion.
The ultrasonographic pelvic examination 
that showed increased uterine volume and diffuse 
heterogeneity of the myometrium did not allow the 
diagnosis of leiomyosarcoma to be considered. 
Information on tumor bizarre architecture and its 
vasculature as well as the diastolic flow and resistance 
indices, analyzed through ultrasound with Doppler or 
magnetic resonance imaging (MRI), could contribute 
to the increased likelihood of a diagnosis of uterine 
sarcoma.26
57
Partial vaginal expulsion of a leiomyosarcoma Autopsy and Case Reports 2013; 3(2): 51-58
6. O’Meara AT. Uterine sarcomas: have we made any progress? 
Curr Opin Obstet Gynecol. 2004;16:1-4. PMid:15128000. 
http://dx.doi.org/10.1097/00001703-200402000-00002
7. Nickie-Psikuta M, Gawrychowski K. Different types and 
different prognosis-study of 310 uterine sarcomas. Eur J 
Gynaecol Oncol. 1993;14(Suppl):105-13. PMid:8200360.
8. Arenas M, Rovirosa A, Hernández V, et al. Uterine sarcomas 
in breast cancer patients treated with tamoxifen. Int J Gynecol 
Cancer. 2006;16:861-5. PMid:16681774. http://dx.doi.
org/10.1111/j.1525-1438.2006.00415.x
9. Moinfar F, Azodi M, Tavassoli FA. Uterine sarcomas. 
Pathology. 2007;39:55. PMid:17365823. http://dx.doi.
org/10.1080/00313020601136146
10. Giuntoli RL 2nd, Metzinger DS, DiMarco CS, et al. 
Retrospective review of 208 patients with leiomyosarcoma 
of the uterus: prognostic indicators, surgical management, 
and adjuvant therapy. Gynecol Oncol. 2003;89:460-9. http://
dx.doi.org/10.1016/S0090-8258(03)00137-9
11. Launonen V, Vierimaa O, Kiuru M, et al. Inherited susceptibility 
to uterine leiomyomas and renal cell cancer. Proc Natl Acad 
Sci USA. 2001;98:3387-92. PMid:11248088 PMCid:30663. 
http://dx.doi.org/10.1073/pnas.051633798
12. Clement P, Oliva E. Mesenchymal lesions of the uterus. 
Histopathology. 2002,41(Suppl. 2),12-31. http://dx.doi.
org/10.1046/j.1365-2559.41.s2.33.x
13. Tropé CG, Abeler VM, Kristensen GB. Diagnosis and 
treatment of sarcoma of the uterus. A review. Acta 
Oncol. 2012;51:694-705. PMid:22793037. http://dx.doi.or
g/10.3109/0284186X.2012.689111
14. McCluggage WG, Robboy SJ. Mesenchymal uterine tumors, 
other than pure smooth muscle neoplasms, and adenomyosis. 
In: Robboy SJ, mutter GL, Prat J, Bentley RC, Russell P, 
Anderson MC, editors. Robboy’s pathology of the female 
reprodutive tract. 2nd ed. Philadelphia: Churchill Livingstone, 
Elsevier; 2009. p. 431. http://dx.doi.org/10.1016/B978-0-
443-07477-6.50022-6
15. Koivisto-Korander R, Butzow R, Koivisto AM, Leminen A. 
Immunohistochemical studies on uterine carcinosarcoma, 
leiomyosarcoma, and endometrial stromal sarcoma: 
expression and prognostic importance of ten different markers. 
Tumour Biol. 2011;32:451-9. PMid:21161468. http://dx.doi.
org/10.1007/s13277-010-0138-1
16. El-Nashar SA, Mariani A. Uterine carcinosarcoma. Clin 
Obstet Gynecol. 2011;54:292-304. PMid:21508698. http://
dx.doi.org/10.1097/GRF.0b013e31821ac635
17. Sobin LH, Gospodarowicz MK, Wittekind Ch, International 
Union Against Cancer (UICC), editors. TNM classification 
of malignant tumours. 7th ed. Hoboken: Wiley-
Blackwell; 2009. 310 p.
18. Kernochan LE, Garcia RL. Carcinosarcomas (malignant 
mixed Mullerian turmor) of the uterus: advances in elucidation 
and in younger patients, the ovaries are preserved. 
In locally advanced disease or in post-menopausal 
patients, most studies showed no difference in the 
survival rate between those whose ovaries are retained 
and those who undergo a bilateral oophorectomy.31
CONCLUSION
Uterine sarcomas are rare neoplasia 
characterized by aggressiveness and poor prognosis. 
In the absence of prospective randomized trials, 
treatment recommendations are based on the results 
of retrospective reviews. Total hysterectomy remains 
the treatment of choice and may be associated, 
depending on the case, to bilateral salpingo-
oophorectomy. Adjunctive therapy, such as radiation 
and chemotherapy, appears to reduce local recurrence; 
however, no survival benefit has been demonstrated.
Despite the rarity of this tumor, uterine 
sarcomas should be considered as a differential 
diagnosis in patients with uterine masses, pelvic 
pain, or bleeding.
The identification of the disease in its early 
stages, liable to curative resection, is extremely 
important. Otherwise, in advanced cases, the prognosis 
is poor, even with the complementary chemotherapy.
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